CN103906746B - 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物 - Google Patents

用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物 Download PDF

Info

Publication number
CN103906746B
CN103906746B CN201280052591.6A CN201280052591A CN103906746B CN 103906746 B CN103906746 B CN 103906746B CN 201280052591 A CN201280052591 A CN 201280052591A CN 103906746 B CN103906746 B CN 103906746B
Authority
CN
China
Prior art keywords
compound
phenyl
formula
imidazol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280052591.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103906746A (zh
Inventor
S·K·巴加尔
M·I·肯普
D·C·米勒
Y·村田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103906746(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Publication of CN103906746A publication Critical patent/CN103906746A/zh
Application granted granted Critical
Publication of CN103906746B publication Critical patent/CN103906746B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280052591.6A 2011-10-26 2012-10-15 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物 Expired - Fee Related CN103906746B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
US61/551,628 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (2)

Publication Number Publication Date
CN103906746A CN103906746A (zh) 2014-07-02
CN103906746B true CN103906746B (zh) 2015-12-09

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280052591.6A Expired - Fee Related CN103906746B (zh) 2011-10-26 2012-10-15 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物

Country Status (28)

Country Link
US (1) US9079878B2 (https=)
EP (1) EP2771335A2 (https=)
JP (1) JP5946538B2 (https=)
KR (1) KR101586966B1 (https=)
CN (1) CN103906746B (https=)
AP (1) AP2014007579A0 (https=)
AU (1) AU2012328034B2 (https=)
BR (1) BR112014009102A2 (https=)
CA (1) CA2850925C (https=)
CL (1) CL2014000956A1 (https=)
CO (1) CO6940427A2 (https=)
CR (1) CR20140185A (https=)
CU (1) CU20140046A7 (https=)
DO (1) DOP2014000085A (https=)
EA (1) EA023375B1 (https=)
EC (1) ECSP14013324A (https=)
GT (1) GT201400079A (https=)
IL (1) IL232267A (https=)
MD (1) MD20140037A2 (https=)
MX (1) MX337469B (https=)
NI (1) NI201400031A (https=)
PE (1) PE20141682A1 (https=)
PH (1) PH12014500919A1 (https=)
SG (1) SG11201401032YA (https=)
TN (1) TN2014000147A1 (https=)
UA (1) UA109220C2 (https=)
WO (1) WO2013061205A2 (https=)
ZA (1) ZA201402281B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014003064A (es) * 2011-09-14 2014-05-07 Dow Agrosciences Llc Metodos y sistemas para formar acidos boronicos y sus intermedios.
CA2931550C (en) 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
US10612042B2 (en) 2014-10-24 2020-04-07 Avectas Limited Delivery across cell plasma membranes
BR112017017619A2 (pt) 2015-02-19 2018-05-08 Purdue Pharma Lp métodos e composições para diminuir esvaziamento gástrico
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
CA3009715A1 (en) 2015-12-30 2017-07-06 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
CN109843914B (zh) 2016-07-06 2024-03-15 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
JP7305534B2 (ja) * 2016-07-06 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
JP7288051B2 (ja) 2018-11-02 2023-06-06 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害薬としての2-アミノ-N-ヘテロアリール-ニコチンアミド類
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
HRP20260068T1 (hr) 2021-06-04 2026-02-27 Vertex Pharmaceuticals Incorporated Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
CA3221938A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
US20240400544A1 (en) 2021-06-04 2024-12-05 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3257285A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CA3256248A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated HETEROARYL COMPOUNDS FOR PAIN RELIEF
JP2025516005A (ja) 2022-04-25 2025-05-23 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083656A2 (fr) * 2001-04-10 2002-10-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'heterocycles a 5 chainons et leur utilisation en tant qu'inhibiteurs de la mao et/ou peroxydation lipidique, leur preparation et leur application comme medicaments
US20050234118A1 (en) * 2002-07-25 2005-10-20 Dennis Bigg Novel aryllimidazole derivatives, preparation and therapeutic used thereof
CN101103112A (zh) * 2004-10-27 2008-01-09 先灵公司 抑制Nav1.8的短干扰核酸组合物和方法
US20110046129A1 (en) * 2005-12-22 2011-02-24 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US7291641B2 (en) * 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
ES2346665T3 (es) * 2004-05-07 2010-10-19 Warner-Lambert Company Llc Derivados de fenol y tiofenol 3- o 4-monosustituidos utiles como ligandos de h3.
DE602007011793D1 (de) 2006-10-18 2011-02-17 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
EP1995241B1 (en) 2007-03-23 2010-03-17 ICAgen, Inc. Inhibitors of ion channels
WO2008135830A1 (en) 2007-05-03 2008-11-13 Pfizer Limited N- [6-amino-s- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083656A2 (fr) * 2001-04-10 2002-10-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives d'heterocycles a 5 chainons et leur utilisation en tant qu'inhibiteurs de la mao et/ou peroxydation lipidique, leur preparation et leur application comme medicaments
US20050234118A1 (en) * 2002-07-25 2005-10-20 Dennis Bigg Novel aryllimidazole derivatives, preparation and therapeutic used thereof
CN101103112A (zh) * 2004-10-27 2008-01-09 先灵公司 抑制Nav1.8的短干扰核酸组合物和方法
US20110046129A1 (en) * 2005-12-22 2011-02-24 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators

Also Published As

Publication number Publication date
PE20141682A1 (es) 2014-11-14
EP2771335A2 (en) 2014-09-03
DOP2014000085A (es) 2014-08-31
AU2012328034B2 (en) 2015-04-23
JP5946538B2 (ja) 2016-07-06
US9079878B2 (en) 2015-07-14
PH12014500919A1 (en) 2014-06-09
MX2014004738A (es) 2014-08-01
WO2013061205A2 (en) 2013-05-02
CN103906746A (zh) 2014-07-02
IL232267A (en) 2016-10-31
CO6940427A2 (es) 2014-05-09
IL232267A0 (en) 2014-06-30
AP2014007579A0 (en) 2014-04-30
NI201400031A (es) 2014-10-01
CU20140046A7 (es) 2014-10-02
SG11201401032YA (en) 2014-07-30
EA023375B1 (ru) 2016-05-31
NZ623090A (en) 2015-10-30
KR20140069234A (ko) 2014-06-09
BR112014009102A2 (pt) 2017-04-18
CA2850925A1 (en) 2013-05-02
UA109220C2 (uk) 2015-07-27
US20140296313A1 (en) 2014-10-02
KR101586966B1 (ko) 2016-01-19
ZA201402281B (en) 2015-11-25
CR20140185A (es) 2014-06-03
MD20140037A2 (ro) 2014-08-31
ECSP14013324A (es) 2014-05-31
HK1198650A1 (en) 2015-05-22
CL2014000956A1 (es) 2014-07-18
WO2013061205A8 (en) 2014-03-27
WO2013061205A3 (en) 2013-06-27
MX337469B (es) 2016-03-02
JP2014530900A (ja) 2014-11-20
EA201490864A1 (ru) 2014-08-29
CA2850925C (en) 2017-01-10
GT201400079A (es) 2015-06-02
AU2012328034A1 (en) 2014-05-15
TN2014000147A1 (fr) 2015-09-30

Similar Documents

Publication Publication Date Title
CN103906746B (zh) 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物
JP6002785B2 (ja) ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
JP6067031B2 (ja) N−アミノスルホニルベンズアミド
JP6058023B2 (ja) スルホンアミド誘導体
JP4056081B1 (ja) ピリジン誘導体
JP5860045B2 (ja) 化合物
JP4657384B2 (ja) ナトリウムチャンネルモジュレーターとしての2−ピリジンカルボキサミド誘導体
JP2013532185A (ja) 化合物
JP2013532186A (ja) 化合物
JP2013536165A (ja) 痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体
JP2013531030A (ja) 電位開口型ナトリウムチャネルの阻害剤としてのn−スルホニルベンズアミド
JP2009514937A (ja) ピラジン誘導体
JP2009523842A (ja) ナトリウムチャネルモジュレーターとしてのピリジン誘導体
JP2009515943A (ja) アミノ酸誘導体
HK1198650B (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
JP2009516675A (ja) 疼痛を治療するためのイソシステイン誘導体
OA16888A (en) (4-phenylimidazol-2-YL) ethylamine derivatives useful as sodium channel modulators
NZ623090B2 (en) (4-phenylimidazol-2-yl)ethylamine derivatives useful as sodium channel modulators
HK1107812A (en) Pyridine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1198650

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1198650

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151209

Termination date: 20171015

CF01 Termination of patent right due to non-payment of annual fee